AriBio Reports Mixed Phase 3 Results for Alzheimer’s Drug

Share on Social Media

AriBio AR1001 Phase 3 POLARIS-AD trial results in early Alzheimer’s disease
Image: Unsplash

AriBio’s AR1001 met the Phase 3 POLARIS-AD efficacy threshold in the Monotherapy population, slowing clinical decline by 31%, but missed significance overall.

Written By: Charvi Kalal, PharmD

Reviewed By: Pharmacally Editorial Team

AriBio Co., Ltd. announced on November 16, 2026, that its investigational oral drug AR1001 met the primary efficacy objective in the prespecified Monotherapy population of the global Phase 3 POLARIS-AD trial (NCT05531526) in early Alzheimer’s disease (AD). In this population, treatment reduced clinical decline by 31% versus placebo at Week 52. However, the treatment difference did not reach statistical significance in the overall trial population of 1,535 participants. The results were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference in Boston.

AR1001: Mechanism and therapeutic rationale

AR1001 is an investigational, once-daily oral small molecule developed as a potential disease-modifying treatment for AD. It is a blood-brain barrier-penetrant phosphodiesterase-5 (PDE5) inhibitor that enhances cyclic guanosine monophosphate (cGMP) signalling. Preclinical research suggests potential effects on cerebral perfusion, neuroprotection, neuroinflammation and tau phosphorylation. AR1001 has not received regulatory approval for AD.

POLARIS-AD: Phase 3 study design

POLARIS-AD was a randomized, double-blind, placebo-controlled Phase 3 trial initiated in December 2022. It enrolled 1,535 participants across approximately 230 clinical sites in 13 countries. Participants received AR1001 30 mg or placebo once daily for 52 weeks.

Registered eligibility criteria included participants aged 55–90 years with mild cognitive impairment or mild dementia consistent with AD, an MMSE score of at least 20, a Clinical Dementia Rating (CDR) global score of 0.5 or 1, and evidence of amyloid pathology through cerebrospinal fluid assessment or amyloid positron emission tomography.

The primary endpoint was change from baseline to Week 52 on the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a measure of cognitive and functional impairment, with higher scores indicating greater impairment. Efficacy was evaluated in two prespecified populations:

  • Overall population (n=1,535): All trial participants.
  • Monotherapy population (n=604): Participants not receiving an acetylcholinesterase inhibitor (AChEI) or memantine at baseline.

The prespecified statistical design allowed the primary efficacy objective to be met in either population, with separate significance thresholds of p=0.02 for the Overall population and p=0.03 for the Monotherapy population. A total of 1,349 participants (87.9%) completed the double-blind treatment period, and 1,284 (95.2% of completers) entered the optional 52-week open-label extension.

Primary efficacy: Positive Monotherapy result, negative overall outcome

In the Monotherapy population, AR1001 demonstrated a statistically significant treatment difference of −0.44 points versus placebo on CDR-SB at Week 52 (p=0.0266), meeting its prespecified significance threshold and corresponding to 31% relative slowing of clinical decline.

In the Overall population, the treatment difference was −0.11 points (p=0.4015), which did not reach statistical significance.

These findings establish a statistically significant treatment effect in the prespecified Monotherapy population, but not across the broader trial population. Whether background symptomatic medication use influences AR1001 treatment response remains uncertain and cannot be established from the topline findings alone.

Secondary endpoints and biomarker findings

Secondary cognitive and functional measures generally favored AR1001, with larger numerical effects in the Monotherapy population. In this population, the treatment difference on the Alzheimer’s Disease Assessment Scale–Cognitive Subscale 13 (ADAS-Cog 13) was −1.16 points (p=0.0798), which was not statistically significant. The Mini-Mental State Examination (MMSE) showed a 0.7-point treatment difference (p=0.0232), described as nominally significant.

Cerebrospinal fluid (CSF) analyses showed increased cGMP levels versus placebo in both the Overall (p<0.0001) and Monotherapy populations (p=0.0058), supporting pharmacodynamic target engagement. CSF p-tau217 treatment differences were −3.52 pg/mL in the Overall population (p=0.1784) and −5.34 pg/mL in the Monotherapy population (p=0.0402), with the latter nominally significant. No difference in the CSF Aβ42/40 ratio was observed at Week 52. These biomarker changes do not independently establish clinical disease modification.

Safety and tolerability

Treatment-emergent adverse events occurred in 69.0% of AR1001 recipients versus 66.4% with placebo. Serious adverse events were comparable (10.0% versus 9.8%), and most events were mild to moderate.

The most common non-serious adverse events with AR1001 included diarrhea (7.7% versus 4.4%), falls (7.3% versus 5.9%) and dizziness (6.1% versus 3.1%). Adverse events led to treatment discontinuation in 5.2% of AR1001 recipients compared with 1.7% receiving placebo. Fatal adverse events occurred in four participants (0.5%) versus two (0.3%), respectively; treatment-relatedness was not specified in the announcement. The higher discontinuation rate warrants further evaluation despite broadly comparable overall adverse event rates.

Development outlook and clinical implications

AriBio plans to present additional analyses at future scientific meetings and discuss the complete findings with the US Food and Drug Administration (FDA). The open-label extension is expected to conclude in the third quarter of 2027. The company has not announced a specific regulatory submission timeline.

The POLARIS-AD results provide a positive efficacy signal for AR1001 in participants with early AD who were not receiving AChEIs or memantine. However, the absence of statistical significance in the overall population limits conclusions about its potential applicability across the broader early AD population. The secondary clinical and biomarker findings also require cautious interpretation because multiplicity-adjusted significance has not been established in the topline announcement.

Although the 31% relative slowing on CDR-SB met the prespecified statistical threshold in the Monotherapy population, its clinical meaningfulness and durability remain to be established. The higher treatment discontinuation rate also warrants further scrutiny. Full trial analyses, longer-term follow-up and regulatory discussions will be important in determining AR1001’s potential role in early AD.

Reference

AriBio’s Oral AR1001 Meets Primary Efficacy Objective in Prespecified Monotherapy Population in Phase 3 POLARIS-AD Trial, 17 November 2026

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer’s Disease (Polaris-AD), ClinicalTrials.gov ID NCT05531526

About the Writer

Charvi Kalal (LinkedIn) is a Pharm.D intern and aspiring medical writer with hands-on experience in medical writing, clinical research, pharmacovigilance, and clinical pharmacy. She has experience in medical content writing through CliMed, along with exposure to ADR monitoring, prescription analysis, patient counselling, literature review, and research documentation. Her research focuses on ADR monitoring and reporting in breast cancer patients receiving targeted therapy. With certifications in GCP, biomedical research, scientific writing, and clinical research, she is passionate about transforming scientific evidence into accurate, engaging, and accessible healthcare content.


Share on Social Media
Scroll to Top